DPCO

New Delhi (Gurpreet Singh): The Supreme Court on Monday expressed sharp dissatisfaction with the Union government's decision to restrict trade margin capping exclusively to anti-cancer drugs, remarking that there was "hardly anything to be happy about" and questioning why similar caps have not been extended across other vital pharmaceutical categories. The Centre submitted before the top court that it has resolved to cap trade margins on anti-cancer drugs at 30 percent of the Maximum Retail Price (MRP), a step considered during the 151st meeting of the National Pharmaceutical Pricing Authority (NPPA) on October 8. According to the government, invoking extraordinary…